依达拉奉联合阿替普酶治疗急性脑梗死23例疗效观察

Clinical Observation of Edaravone Combined with Batroxobin for Treating Acute Cerebral Infarction in 23 Cases

目的探讨依达拉奉联合阿替普酶治疗急性脑梗死的临床疗效。方法选择医院神经内科2015年2月至2016年4月收治的49例急性脑梗死患者,随机分为试验组23例和对照组26例。对照组给予阿替普酶治疗,试验组患者在对照组基础上加用依达拉奉治疗。结果治疗后,试验组神经功能缺损评分(NIHSS)、白细胞介素6(IL-6)与超敏C反应蛋白(hs-CRP)水平均优于对照组(P<0.05)。结论依达拉奉联合阿替普酶治疗急性脑梗死,疗效颇佳,值得临床应用。

Objective To investigate the clinical efficacy of edaravone combined with batroxobin in the treatment of acute cerebral infarction.Methods Totally 49 patients with acute cerebral infarction in our hospital from February 2015 to April 2016 were randomly divided into the experimental group（23 cases） and the control group（26 cases）.The control group was treated with batroxobin,on this basis,the experimental group was treated with edaravone.Results After treatment,the NIHSS score,IL-6 and hs-CRP in the experimental group were better than those in the control group（P 〈 0.05）.Conclusion Edaravone combined with batroxobin in the treatment of acute cerebral infarction has good effect,it is worthy of clinical promtion.